BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 28428040)

  • 1. Design, synthesis, and docking studies of quinazoline analogues bearing aryl semicarbazone scaffolds as potent EGFR inhibitors.
    Tu Y; Wang C; Xu S; Lan Z; Li W; Han J; Zhou Y; Zheng P; Zhu W
    Bioorg Med Chem; 2017 Jun; 25(12):3148-3157. PubMed ID: 28428040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and docking studies of afatinib analogs bearing cinnamamide moiety as potent EGFR inhibitors.
    Tu Y; OuYang Y; Xu S; Zhu Y; Li G; Sun C; Zheng P; Zhu W
    Bioorg Med Chem; 2016 Apr; 24(7):1495-503. PubMed ID: 26906472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, antiproliferative activity and docking studies of quinazoline derivatives bearing 2,3-dihydro-indole or 1,2,3,4-tetrahydroquinoline as potential EGFR inhibitors.
    OuYang Y; Zou W; Peng L; Yang Z; Tang Q; Chen M; Jia S; Zhang H; Lan Z; Zheng P; Zhu W
    Eur J Med Chem; 2018 Jun; 154():29-43. PubMed ID: 29775935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
    Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L
    Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
    Zhu W; Wang W; Xu S; Wang J; Tang Q; Wu C; Zhao Y; Zheng P
    Bioorg Med Chem; 2016 Apr; 24(8):1749-56. PubMed ID: 26964675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
    Chang J; Ren H; Zhao M; Chong Y; Zhao W; He Y; Zhao Y; Zhang H; Qi C
    Eur J Med Chem; 2017 Sep; 138():669-688. PubMed ID: 28711702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
    Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
    Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and docking studies of phenylpicolinamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
    Zhu W; Wang W; Xu S; Tang Q; Luo R; Wang M; Gong P; Zheng P
    Bioorg Med Chem; 2016 Feb; 24(4):812-9. PubMed ID: 26810712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel quinazoline derivatives bearing semicarbazone moiety as potent EGFR kinase inhibitors.
    Tu Y; Wang C; Yang Z; Zhao B; Lai L; Yang Q; Zheng P; Zhu W
    Comput Struct Biotechnol J; 2018; 16():462-478. PubMed ID: 30455856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, Synthesis and Biological Evaluation of Novel 4-phenoxypyridine Derivatives Containing Semicarbazones Moiety as Potential c-Met Kinase Inhibitors.
    Li J; Li J; Zhang J; Shi J; Ding S; Liu Y; Chen Y; Liu J
    Anticancer Agents Med Chem; 2020; 20(5):559-570. PubMed ID: 31893997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, antiproliferative activity, molecular docking and cell cycle analysis of some novel (morpholinosulfonyl) isatins with potential EGFR inhibitory activity.
    Ammar YA; Sh El-Sharief AM; Belal A; Abbas SY; Mohamed YA; Mehany ABM; Ragab A
    Eur J Med Chem; 2018 Aug; 156():918-932. PubMed ID: 30096580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
    Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
    Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
    Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
    Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
    Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 6,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
    Zhang Y; Chen L; Xu H; Li X; Zhao L; Wang W; Li B; Zhang X
    Eur J Med Chem; 2018 Mar; 147():77-89. PubMed ID: 29421573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR inhibition studies by hybrid scaffolds for their activity against ovarian cancer.
    Zhang F; Zhang H; Wang F
    J BUON; 2016; 21(6):1482-1490. PubMed ID: 28039712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
    Hou W; Ren Y; Zhang Z; Sun H; Ma Y; Yan B
    Bioorg Med Chem; 2018 May; 26(8):1740-1750. PubMed ID: 29523467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and evaluation of anti-proliferative activity of 2-aryl-4-aminoquinazoline derivatives as EGFR inhibitors.
    Zhou Z; He J; Yang F; Pan Q; Yang Z; Zheng P; Xu S; Zhu W
    Bioorg Chem; 2021 Jul; 112():104848. PubMed ID: 33819737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
    Xu P; Chu J; Li Y; Wang Y; He Y; Qi C; Chang J
    Bioorg Med Chem; 2019 Oct; 27(20):114938. PubMed ID: 31488358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells.
    Ismail RSM; Abou-Seri SM; Eldehna WM; Ismail NSM; Elgazwi SM; Ghabbour HA; Ahmed MS; Halaweish FT; Abou El Ella DA
    Eur J Med Chem; 2018 Jul; 155():782-796. PubMed ID: 30047410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.